Giorgio Reggiardo
Overview
Explore the profile of Giorgio Reggiardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landi A, Reggiardo G, Didio A, DErcole A, Ceci A, Govere G, et al.
Pediatr Rep
. 2025 Feb;
17(1).
PMID: 39997631
Background/objectives: This work aimed to analyze pediatric Post-Authorization Studies (PASs) registered in the European Union electronic Register of Post-Authorization Studies (EU PAS Register) from September 2010 to April 2023 to...
2.
Bolasco P, Reggiardo G
Nutrients
. 2024 Sep;
16(17).
PMID: 39275299
Dietary factors may be implicated in the formation of kidney stones and should be closely monitored. To achieve this aim, patients are routinely assessed by means of generic dietary recall,...
3.
Murtas S, Reggiardo G, Contu R, Cadeddu M, Secci R, Putzu P, et al.
Clin Nutr ESPEN
. 2024 Jul;
63:354-363.
PMID: 38985667
Background: A series of interesting literature reports acknowledges the notable loss of essential and non-essential amino acids (EAAs and NEAAs) during hemodialysis sessions. These losses may exceed 800 g/year, thus...
4.
Giannuzzi V, Bertolani A, Torretta S, Reggiardo G, Toich E, Bonifazi D, et al.
Front Med (Lausanne)
. 2024 Apr;
11:1369547.
PMID: 38606157
Introduction: The European Medicines Agency (EMA) offers scientific advice to support the qualification procedure of novel methodologies, such as preclinical and models, biomarkers, and pharmacometric methods, thereby endorsing their acceptability...
5.
Reggiardo G, Aghina B, Landi F
J Wound Care
. 2024 Apr;
33(4):210-219.
PMID: 38573902
Objective: The aim of this cost-effectiveness analysis was to estimate the monetary cost required to achieve a gain in health benefit. An analytic model to evaluate the cost-effectiveness of a...
6.
Lo Giudice M, Cocco A, Reggiardo G, Lalli S, Albanese A
Clin Drug Investig
. 2023 Nov;
43(12):893-903.
PMID: 37973672
Phase II studies on tauro-urso-deoxycholic acid (TUDCA) raised the promise of safety and efficacy in patients with amyotrophic lateral sclerosis, a currently incurable and devastating disease. We review the available...
7.
Reggiardo G, Lo Giudice M, Lalli S, Rinaldi G, Albanese A
Front Neurol
. 2023 May;
14:1163855.
PMID: 37153676
Recent phase II pilot clinical trials suggested that tauro-urso-deoxycholic acid (TUDCA) might slow functional decline and increase survival in patients with amyotrophic lateral sclerosis (ALS). We performed a multivariate analysis...
8.
Minotti G, Reggiardo G, Camilli M, Salvatorelli E, Menna P
JACC CardioOncol
. 2022 May;
4(1):139-140.
PMID: 35492821
No abstract available.
9.
Minotti G, Salvatorelli E, Reggiardo G, Mangiacapra F, Camilli M, Menna P
J Pharmacol Exp Ther
. 2022 Mar;
381(3):266-273.
PMID: 35332076
Diastolic dysfunction (DD) was reported to precede heart failure (HF) in patients with cancer who were treated with chemotherapy. We aimed at defining risk versus dose relationships and risk predictors...
10.
Rosati G, Corsi D, Avallone A, Brugnatelli S, DellAquila E, Cinausero M, et al.
J Geriatr Oncol
. 2021 Oct;
13(3):302-307.
PMID: 34716122
Objectives: To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in...